Page last updated: 2024-11-02

pioglitazone and Antisocial Behavior

pioglitazone has been researched along with Antisocial Behavior in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Antisocial Behavior: Behavior that sharply deviates from social norms and violates rights of others

Research Excerpts

Excerpt	Relevance	Reference
"Pioglitazone did not increase weight or produce any other significant side-effects."	2.78	Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. ( Bark, N; Davis, JM; Dwivedi, S; Hu, Q; Jin, H; Li, C; Lohr, J; Mortiere, C; Shekhar, A; Smith, RC, 2013)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Smith, RC	1
Jin, H	1
Li, C	1
Bark, N	1
Shekhar, A	1
Dwivedi, S	1
Mortiere, C	1
Lohr, J	1
Hu, Q	1
Davis, JM	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function[NCT00231894]			Phase 4	56 participants (Actual)	Interventional	2005-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

2 Hour Glucose From Glucose Tolerance Test China Sample

difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment

Intervention	mg/dL (Least Squares Mean)
Pioglitazone	-6.82
Placebo	-40.72

2 Hour Glucose From Glucose Tolerance Test US Sample

difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment

Intervention	mg/dL (Least Squares Mean)
Pioglitazone	-24.19
Placebo	15.19

Change From Baseline in Serum Glucose at 3 Months ( 3 Months -Baseline) China Sample

(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment

Intervention	mg/dL (Least Squares Mean)
Pioglitazone	-13.33
Placebo	-11.5

Change From Baseline in Serum Glucose at 3 Months (3 Months-baseline) US Sample

(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment

Intervention	mg/dL (Least Squares Mean)
Pioglitazone	0.02
Placebo	24.20

Change From Baseline in Serum HDL at 3 Months (3 Months-baseline) China Site

(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment

Intervention	mg/dL (Least Squares Mean)
Pioglitazone	6.52
Placebo	7.72

Change From Baseline in Serum HDL at 3 Months (3 Months-baseline) US Sample

serum high density lipoprotein (HDL) (NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment

Intervention	mg/dL (Least Squares Mean)
Piogltiazone	4.62
Placebo	-2.59

Change From Baseline in Serum Triglycerides at 3 Months ( 3 Months-baseline) US Sample

(NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment

Intervention	mg/dL (Least Squares Mean)
Pioglitazone	-49.65
Placebo	30.99

Change From Baseline in Serum Triglycerides at 3 Months (3 Months-baseline) China Sample

(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment

Intervention	mg/dL (Least Squares Mean)
Pioglitazone	32.56
Placebo	-79.12

Change in RBANS List Recognition Scores at 3 Months (3 Months-baseline) US Sample

The scale is Repeatable Battery for the Assessment to Neuropsychological Status (RBANS). This scale measure cognitive function in patients with schizophrenia. Range for list learning sub-score is 0 to 20 . Higher values indicate better performance. For change score (3 months -baseline) positive values indicate improved performance for this cognitive function and negative values indicate poorer performance on this cognitive function. (NCT00231894)
Timeframe: pre-treatment and 3 months of treatment

Intervention	Units on RBANS scale (Least Squares Mean)
Pioglitazone	0.27
Placebo	-1.11

Trials

1 trial available for pioglitazone and Antisocial Behavior

Article	Year
Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. Schizophrenia research, 2013, Volume: 143, Issue:1 Topics: Adult; Analysis of Variance; Antipsychotic Agents; Antisocial Personality Disorder; Case-Control Stu	2013